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Abstract
Introduction: With the aging US population, chronic liver diseases are becoming more commonly diagnosed in the geriatric
population. Advanced age leads to changes in liver blood flow, volume, morphology and normal physiology. This predisposes
elderly patients to develop certain chronic liver diseases. Also, the clinical course and management differ in an older patient
when compared to a younger patient. Some causes of chronic liver disease in the geriatric population include Hepatitis A, B, C,
Non-Alcoholic Fatty liver disease, prolonged alcohol use and inflammation. Many chronic liver diseases are characterized by a
slow, indolent course of progression with non-specific symptoms and thus may lead to diagnosis at a later age. The presence of
an advanced liver disease, cirrhosis, and hepatocellular carcinoma are becoming more frequent in older patients and often the
first clinical presentation.
Aim: The aim of this study is to highlight hepatic diseases in the geriatric population to better understand the scope of the clinical management including liver transplantation.
Method: PubMed, MEDLINE, EMBASE, and EMBASE classic were searched to research published articles, case reports,
cross-sectional and case-control studies reporting regarding aging and the liver diseases.
Result: Decreases in the functioning of the liver and other organs, as well as, alterations in immune functions should be taken
into consideration in the management of the liver diseases. Aging has been shown to not only enhance vulnerability to acute liver
injury but also increase the susceptibility of the fibrotic response. Aging has a significant impact on the risk and poor prognosis
of various liver diseases including NAFLD, ALD, HCV, and liver transplantation. The diagnosis of advanced liver disease is
important to make in the elderly population since many of the condition’s features are treatable and can lead to improved quality of life and, most importantly, decrease the likelihood of acute care hospitalization, which carries a high risk of nosocomial
infections and therapeutic mishaps in the aged population.
Conclusion: Geriatric patients show various changes in the liver, which play a role in the clinical characteristics of liver diseases
in these patients. Geriatric patients with risk factors for hepatitis should be screened for liver disease, along with those that have
a family history of liver diseases, or a history of long-term or heavy alcohol consumption. Age cannot be a single exclusion criterion from the liver transplantation, and an individualization strategy, which takes into consideration all risk factors of a recipient,
needs to be considered. We suggest geriatric patients should be a candidate for liver transplant, and the healthcare team treating
our elderly generation to collaborate for these patients for them to have a smoother transition both in pre-transplant phase and
post-transplant phase.
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Introduction
Aging causes time-dependent, inevitable physiologic organ
dysfunction that alters normal homeostasis and is a major risk
factor for cancer development [1]. In the United States, as of 2009,
there are 39.6 million people older than the age of 65, equating to
13% of the country’s total population. This number is expected
to increase to 72 million or 19% of the total US population by
2030 [2-4]. Aging has shown increase vulnerability to acute liver
injury as well as progression to liver fibrosis. This is associated
with associated with poor prognosis of various liver diseases
including Nonalcoholic Fatty Liver Disease (NAFLD), Alcoholic
Liver Disease (ALD), Hepatitis C (HCV), Hepatocellular
Carcinoma (HCC) and Liver Transplantation (LT). Studies have
compared changes in the liver due to liver diseases with the
process of aging [5]. Approximately, 8 million Americans suffer
from chronic hepatic diseases, of which, more than half a million
people have cirrhosis and nearly, 31 thousand Americans die
each year from cirrhosis [6-8]. Old age seems to favor NAFLD,
NASH, and ultimately HCC, in agreement with the inflammatory
aging theory, according to which aging accrues inflammation [5].
The higher vulnerability to environmental factors (Especially
oxidative stress), the reduction in the rate of hepatic blood flow,
the reduced mitochondrial capacity and the impaired immunity are
all mechanisms possibly involved in a faster progression of liver
damage [9].
Aging and Liver Volume, Blood Flow, And Function
Both liver volume and blood flow decrease significantly
with age. Hepatic blood flow is estimated to be decreased by
35%-50% in the elderly and may be responsible for age-related
reductions in liver volume [10]. The neural fat and cholesterol
volumes in the liver gradually expand as one gets older, and
therefore causes an increase in total serum cholesterol and highdensity lipoprotein cholesterol. Meanwhile, the metabolism of the
low-density lipoprotein cholesterol decreases by 35%. The serum
γ-glutamyltransferase and alkaline phosphatase levels increase
with aging, while Alanine Aminotransferase (ALT) concentrations
and serum bilirubin are gradually reduced with age, independent of
components of the metabolic syndrome, the serum aminotransferase
maintains normal level and albumin remains within normal limits
or is slightly decreased due to aging [11]. Humans show a slight
decrease in the serum albumin concentration or maintain the
normal level in the natural aging process [11].
Alanine Aminotransferase (ALT) concentrations have been
reported to decrease with age, independent of components of the
metabolic syndrome. These findings suggest the need to identify
an optimal cut-off point for normal ALT in Geriatric patients [12].
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Hepatic Encephalopathy (HE) also can occur because of portal
hypertension. Resistance to blood flow leads to shunting of blood
around the liver, allowing blood from the gut containing ammonia
and other byproducts of bacterial metabolism to bypass the liver
and reach the systemic circulation [7]. Exposing the brain to these
chemicals can result interfere with the normal synaptic transmission
of electrical and chemical signaling. As a result, cognition and
memory are affected, leading to memory loss, impaired thinking,
and an inability to perform fine motor tasks [13,14].
Aging-Related Changes in Liver Cells
Aging-related changes in liver cells include volume changes,
polyploidy, accumulation of dense bodies (Lipofuscin) inside liver
cells, a decreased area of the smooth endoplasmic reticulum, and a
declining number and dysfunction of mitochondria [15]. Compared
with the studies on liver cells, relatively little is known about what
kind of effect aging has on liver sinusoidal endothelial cells, Kupffer
cells, and hepatic stellate cells [16]. The functionality of Kupffer
cells is to remove antigen–antibody complexes or nanoparticles
such as senescent cell fragments in the liver sinusoidal vascular
system and is important to point out that aging increases the number
and activation level of Kupffer cells [17]. A study by Sotaniemi, et
al [18], suggested that drug metabolism is reduced by up to 30%
after 70 years of age, and that a reduction in liver cytochrome P450
may also contribute to decreased drug metabolism. Cytochrome
P450 activity was shown to be 32% lower in subjects > 70 years
than in subjects aged 20-29 years [18].
First-pass hepatic uptake (Phase I) of drugs has been
reported to be decreased in the elderly, possibly due to reduced
liver volume and hepatic blood flow, leading to a decline in
hepatic drug metabolism [19]. Metabolism of drugs with low
phase I hepatic metabolism is likely to be impaired mainly by
liver volume reduction [19]. Volume and blood flow changes
coupled with decreased cytochrome P450 activity can affect drug
metabolism, increasing susceptibility to drug-induced liver injury
[20]. Immune responses against pathogens or neoplastic cells
are decreased in the elderly, although individuals may also be
predisposed to autoimmunity through impairment of dendritic cell
maturation and reduction of regulatory T cells [21]. Such changes
in immune functions could alter the pathogenesis of viral hepatitis
and autoimmune liver diseases and development of hepatocellular
carcinoma [22,23]. Geriatric patients have significantly decreased
reserve functions of various other organs as well, reducing their
tolerability to treatments for liver diseases [24].

Hepatic Diseases of Elderly
NAFLD
Non-alcoholic fatty liver disease is a clinical syndrome
predicted to be the next global epidemic affecting millions of
people worldwide, especially the geriatric population [25,26]. The
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natural course of this disease including its subtype, Non-Alcoholic
Steatohepatitis (NASH), is not clearly defined especially in the
elderly segment of the US population [26]. NAFLD affects mainly
the middle-aged and the elderly and previously was reported be
benign, however more recent studies suggest an increased mortality
in the patients older than 60-year [27]. With advancing age come
more risk factors for its development. Aging increases risk factors
which predispose progression to NAFLD. Older patients have
more severe biochemical, hematological, and histological changes
[28]. The pivotal role of inflammation in the pathogenesis of liver
steatosis has been emphasized in the literature; the link between
insulin resistance and inflammation and the possible role of
C‐Jun N‐Terminal Kinases (JNKs) in the progression of this
condition has been clearly defined, along with the involvement of
endoplasmic reticulum stress and of the unfolded protein response
[29]. Aging-related alterations of the pro-inflammatory vs antiinflammatory balance, described as the inflammatory aging theory
may represent the biological background of these findings [30].
Current guidelines for treatments for NAFLD are to control body
weight and treatment of metabolic disorders by changing lifestyle
and improve insulin resistance [31,32].

rare cases which physicians should pay close attention for is overly
excessive use of acetaminophen [53,54]. The primary treatment
for alcoholic liver disease is abstinence from drinking and provide
sufficient nutrients and vitamins, but in geriatric patients, this is a
major problem due to prolonged use of alcohol and late diagnosis
of ALF [55]. Half of the elderly patients who develop cirrhosis die
within 1 year of diagnosis [56]. Glucocorticoid treatment can be
helpful for some patients with mild to moderate alcohol hepatitis
whose Maddrey’s discriminant function scores are higher than 32
[57]. However current research has described glucocorticoidsinduced hyperglycemia elderly patients and physicians should
be aware of this complication [58]. For patients who have a
contraindication for steroids, pentoxifylline, a TNF-α Inhibitor
(TNFI), can be considered as an alternative treatment which the
retention rate of TNFI in the elderly is comparable with that in
younger patients [59]. It is imperative to identify geriatric patients
with ALF as soon as possible to transfer them to a liver transplant
center for an evaluation and life style modification. Emergent liver
transplant in the geriatric patient with ALF may place the patient at
risk for severe complications in the postoperative period [60], but
in the long run, may help to prevent mortality.

Metformin and thiazolidinedione’s are insulin sensitizers,
which metformin is known to be effective in reducing body weight
and improving insulin resistance [33], but its histological effect of
improving necrotic inflammation in the NASH has not been proven
[34,35]. In very rare cases, it can cause lactic acidosis in the elderly
[36,37]. Another treatment option would be bariatric surgery, but
is important to note that bariatric surgery causes an upsurge in the
morbidity rate among geriatric patients compared with younger
patients, and is no significant difference in the mortality rate except
for those with patients with cardiovascular diseases [38,39]. Liver
transplantation can be an option for patients with decompensated
liver cirrhosis due to NASH and, it is also worthy to not that,
in the geriatric patients, careful consideration should be paid in
consideration of common age-related comorbidities, which has a
significant influence on their survival and hospitalization period
after liver transplantation, due to cardiovascular complications
which they will have [40,41]. More accurate understanding of
the molecular pathways, gut microbiome analysis, and precise
investigation of the mechanisms of geriatric NAFLD will help
in identifying the most appropriate diagnostic and therapeutic
approach for individual geriatric patients [42-46]. With aging,
the liver undergoes substantial changes in structure and function
that are associated with significant impairment of detoxification
activities and many hepatic metabolic dysfunctions [47-49].

Hepatitis A

Acute Liver Failure
Acute Liver Failure (ALF), is an uncommon condition with
potentially devastating consequences, including an increased rate
of short-term morbidity and mortality [50-52]. Common causes
for ALF in elderly is excessive alcohol consumption and in some
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Although Acute Hepatitis A (HAV) infection is usually selflimiting in general population. However, elderly patients with
acute HAV infection can experience hepatocellular dysfunction
with frequent jaundice and coagulopathy, as well as an increased
incidence of complications, such as prolonged pancreatitis,
cholestasis, and ascites [61]. During 1994 and 1995, Memphis
and Shelby County, Tennessee, experienced an epidemic of
HAV, which 42% of patients aged 70 years or older required
hospitalization compared with 3%-20% of adults aged 40-49 years
[62]. Vaccination for HAV should be offered for those who plan
to travel to endemic areas, especially patients living in nursing
homes.
Hepatitis B
Acute Hepatitis B Virus (HBV) infection is very uncommon
in the geriatric patients because the opportunities for acquiring
HBV infection are estimated to be low in this population. However,
HBV infections have been reported in residents of nursing homes
[63]. The rate of progression to chronic hepatitis B is higher in
the elderly vs younger patients [64]. A report of an outbreak in
a nursing home showed that 59% of patients older than 65 years
of age developed chronic HBV infection [64]. Regarding the lab
results of elderly patients with HBV infection, older age and male,
in addition to serum HBV DNA levels, are regarded as risk factors
not only for progression to cirrhosis [65], but the development
of HCC [66]. Nucleoside analogs are effective in treating HBV
infected patients, with similar efficacy in the elderly as in younger
patients [67]. Interferon-based therapy may also be effective for
Volume 03; Issue 02
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the treatment of chronic HBV infection, however, its therapeutic
effects are inferior in elderly patients [68]. Vaccinations should be
considered if patients have not been vaccinated.
Hepatitis C
The population infected with HCV is aging as most in the US
acquired the infection during World War II [69]. A total of 320,000
deaths, 157,000 cases of HCC, and 203,000 cases of cirrhosis
are predicted in the US for the upcoming 35 years, despite the
highly effective and readily available treatment regimens [70]. An
increased number of Americans with advanced liver diseases in part
can be attributed to the 3.3% prevalence of HCV in the geriatric
population [71]. According to a research by Poynard, et al. [9], age
itself is more important than duration of infection for predicting
the occurrence of cirrhosis. This will create a tremendous burden
on the healthcare system, including skilled nursing and longterm care facilities [72-75]. In the US, most patients with HCV
infection were born between 1945 and 1965, who acquired the
infection during the 1970s and 1980s from exposure to blood or
blood products [76-78]. Evidence shows that treatment of HCV
can prevent the progression of end-stage liver disease in geriatric
patients [79]. Since the first introduction of the interferon-alone
treatment, the antiviral treatments for chronic hepatitis C have
developed dramatically through the combination therapy of peginterferon-α and ribavirin to direct-acting antiviral agents such as
protease inhibitors and polymerase inhibitors.
When the elderly people aged more than 65 years are treated
with a combination therapy of peg-interferon-α and ribavirin, their
Sustained Virological Response (SVR) is lower than those under
65 years old (Genotype 1: 22.9 vs. 47.3%; genotype 2: 65.6 vs.
82.9%), whereas their treatment termination rate is higher due
to side-effects (genotype 1: 42.9 vs. 24.1%; genotype 2: 24.4 vs.
10.8%) [80-82]. The combination of three agents such as peginterferon-α., telaprevir, and ribavirin is given to genotype 1 patients
showed no significant difference in their SVR between the young
and elderly [83]. Also, this treatment regime was discontinued
due to complications such as severe malaise [84-86]. According
to a research by Pawlotsky [87], it is important to state that, alloral, interferon-free combinations of drugs are expected to cure
more than 90% of infections, but this has not been tested in elderly
patients [87]. Current research supports that the supplementation
of vitamin D and vitamin B12 increases the SVR, and as elderly
people have a lack of these vitamins, they should be taking these
supplements [88-92].
SVR has been shown to improve biochemical characteristics
and portal hypertension in some patients diagnosed with HCV, it
is unclear in which specific patients may benefit from treatment
with a history of decompensated liver disease [93]. It is thoroughly
documented that HCV infection has a negative impact on the
quality of life of elderly patients, until this date, the complexity of
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treatment and the lack of supportive data in elderly patients have
significantly limited the treatment options [84]. Now that the era
of baby boomers and populations is rapidly changing, and that
new IFN-free treatment options are becoming widely available,
the limited but available evidence concerning the benefit of viral
eradication in the elderly population should be carefully considered
[69]. The faster the health care system changes their policy with
respect to an a priori obstacle for anti-HCV treatment in the elderly,
the sooner we will begin to help many geriatric patients diagnosed
with HCV [69]. HCV infection is the most common indication for
Orthotopic Liver Transplantation (OLT) in the United States [94].
Recent studies from selected centers have suggested that older
donor age is associated with worse outcomes after transplantation
for HCV [95].
According to a research by Dultz, et al. [96] both older donor
age and older recipient age plus markers of severity of disease,
including requirement for mechanical ventilation and renal
insufficiency, are negatively associated with survival after liver
transplantation [94]. According to a research by Pyrsopoulos, et
al. [97] the combination of LED/SOF with RBV for 12 weeks or
ledipasvir/sofosbuvir for 24 weeks is very effective and safe in
treating OLT recipients with recurrent HCV [97]. These factors
should be considered when assessing OLT recipient and donor
candidacy in patients with HCV. Concerted efforts are necessary
to increase diagnosis and treatment rates, optimize care of patients
with cirrhosis and HCC and provide care to liver transplant
recipients to reduce the overall HCV-related disease burden in the
United States [96].
Cholestatic Liver Disease
Primary Sclerosing Cholangitis (PSC) and Primary Biliary
Cirrhosis (PBC) are chronic diseases which can manifest in adult
patients [98]. In a recent study by Tanaka, et al. [98] they reported
that conclude that PSC in the young resembles those in Europe and
the USA in terms of the onset age and prevalence of IBD, while PSC
in the elderly is really unique in Japan. Presenting complications of
elderly patients with PSC is no different than those of the younger
patients [99], but there is certain degree of cholangiocarcinoma
presentation in older patients [100-102]. Eventually all patients
with PSC will require LT, and is better for the elderly patient to
receive the LT before the age of 60 [99]. According to a research
by Newton, et al. [103] they reported that 35% of patients out of
1000 examined had PBC. Symptoms of clinical presentation was
no different for young patients versus the elderly [103]. Although
there has been reported that a 92 year-old men with PBC after
under undergoing Computed Tomography (CT) and ultrasound
scans of his abdomen revealed a large hepatic tumor, which
was confirmed on liver biopsy to be HCC [104]. Furthermore,
biomarkers reflecting disease activity and prognosis in Primary
Sclerosing Cholangitis (PSC) have not been firmly established and
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due to complex interplay which exists between IBD, PSC, and LT
which requires explanation with further research.
Hepatocellular Carcinoma
With age the risk of HCC increases significantly, and this
is independent of prolonged HCV infection as a shorter interval
between acquiring HCV infection and the diagnosis of HCC has
been demonstrated in elderly patients [105]. Many elderly HCC
patients with intermediate to terminal stage at their initial diagnosis
will have more compromised liver regeneration and comorbidities
compared with those of younger age [106]. Elderly patients require
long-term follow-up even after viral eradication and especially
male patients with liver cirrhosis since research has shown that
they are prone to developing HCC [107]. Hepatic resection for
HCC can be performed safely and effectively in elderly patients
[108-110]. A recent report by Borzio, et al. [111] showed that age
did not predict short-mid-term survival within 24 months, while
it was a significant independent predictor of long-term survival.
Also age had a substantial long-term survival effect mainly on
early HCC stages (Barcelona Clinic for Liver Cancer [BCLC]
0-A), its influence on BCLC B stage was shown to be lower, while
it was negligible for advanced terminal stages Age should not
impact on short-mid-term prognosis of elderly patients with HCC
and should not represent a restriction to the management [112].
The pool of elderly patients with the history of HCC receiving a
liver transplantation is increasing [113]. This can be attributed to
the improvement of HCC surveillance approaches and diagnostic
techniques leading to earlier diagnoses of HCC in the elderly
population.
Geriatric Liver Transplant
Liver Transplant (LT) is a standard treatment for EndStage Liver Disease (ESLD). At present, 1-year survival rate is
approximately 90% and 10-year survival rate may exceed 70%
in many indications [114,115]. Patients with ESLD will require
liver transplantation to prevent morbidity and mortality associated
with end-stage-liver disease [116]. The proportion of adult liver
transplantation recipients in the United States older than 60 years
of age increased from 10% in 1990 to more than 20% by 1999
[117]. The era when an ideal liver donor was younger than the
age of 40 years seems to have be gone out of current practice
management [118]. Many transplant programs have expanded
eligibility to include patients previously ineligible because of
advanced age [119]. Several studies showed that outcomes after
LT with livers of patients older than 70-years are comparable, and
sometimes even better compared to younger donors, with 1-year
and 3-year patient and graft survival ranging 66-95% and 58-91%,
respectively [120].
According to a research by Adani, et al. [121], clinical
outcomes after liver transplantation in the elderly are nearly
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similar to young people, considering if individual surgery risks
are equivalent [121]. United Network for Organ Sharing Database
conducted a study which revealed prognostic factors: they found
that diabetes mellitus, the ventilator status, history of HCV,
creatinine at least 1.6 mg/dl, and combined donor age and the
recipient age are the most prevailing prognostic indicators among
the recipients of LT older than 60-years old [122]. If the numbers
of positive indicators among them are 0, 1, and 2, their 5-year
survival rates are recorded at 75, 69, and 58%, respectively. If
the number of positive indicators is more than three, the elderly
patients 5-year survival rate was below 50% [123].
Although it is important to note that geriatric patients may
have multiple risk factors, including artery disease or malignancy,
coronary disease and face age-related quality of life impairments,
such as incontinence, gate instability, immobility, dementia, and
many are on regimen of polypharmacy [124]. It is important
for the healthcare team to also take in account these parameters
when considering the patient for LT. A successful LT depends
on the liver’s structure and hepatic function, but as research
indicate these parameters decline with the process of aging
[125]. Considering that there is a rise in elderly patients the aging
population is increasingly suffering from cerebrovascular disease
[126-131], the use of chronologically old, but biologically young
liver donors would expand the donor pool and, hopefully, reduce
waitlist mortality. Advanced age alone should not be considered
a contraindication for LT due to potentially poor quality of life
outcomes [132]. Further research is necessary to confirm whether
and which geriatric-like measures can be used to select livers of
older donors for LT.

Conclusion
Geriatric patients show various changes in the liver, which
play a role in the clinical characteristics of liver diseases in these
patients. Decreases in the functioning of the liver and other organs,
as well as, alterations in immune functions should be taken into
consideration in the management of the liver diseases. Aging
has been shown to not only enhance vulnerability to acute liver
injury but also increase the susceptibility of the fibrotic response.
Aging has a significant impact on the risk and poor prognosis
of various liver diseases including NAFLD, ALD, HCV, and
liver transplantation. The diagnosis of advanced liver disease is
important to make in the elderly population since many of the
condition’s features are treatable and can lead to improved quality
of life and, most importantly, decrease the likelihood of acute care
hospitalization, which carries a high risk of nosocomial infections
and therapeutic mishaps in the aged population. Geriatric patients
with risk factors for hepatitis should be screened for liver disease,
along with those that have a family history of liver diseases, or a
history of long-term or heavy alcohol consumption. Age cannot
be a single exclusion criterion from the liver transplantation, and
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Citation: Ghavimi S, Azimi H, Patel N, Shulik O (2019) Geriatric Hepatology: The Hepatic Diseases of the Elderly and Liver Transplant. J Dig Dis Hepatol 3: 167.
DOI:10.29011/2574-3511.000067

an individualization strategy, which takes into consideration all
risk factors of a recipient, needs to be considered. We suggest
geriatric patients should be a candidate for liver transplant, and the
healthcare team treating our elderly generation to collaborate for
these patients for them to have a smoother transition both in pretransplant phase and post-transplant phase.
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